Zai Lab announces departure of COO Josh Smiley

Zai Lab (ZLAB) announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the company, effective Friday, May 22. Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503, with a first-in-human data readout from the global Phase 1/1b study. The company is also preparing for the launch of COBENFY in China and for multiple anticipated regional regulatory approvals and expected data readouts.